CZ2004457A3 - Použití inhibitorů fotodiesterasy IV - Google Patents

Použití inhibitorů fotodiesterasy IV Download PDF

Info

Publication number
CZ2004457A3
CZ2004457A3 CZ2004457A CZ2004457A CZ2004457A3 CZ 2004457 A3 CZ2004457 A3 CZ 2004457A3 CZ 2004457 A CZ2004457 A CZ 2004457A CZ 2004457 A CZ2004457 A CZ 2004457A CZ 2004457 A3 CZ2004457 A3 CZ 2004457A3
Authority
CZ
Czechia
Prior art keywords
ethyl
dihydro
tetrahydropyridazin
dimethoxyphenyl
methoxyphenyl
Prior art date
Application number
CZ2004457A
Other languages
Czech (cs)
English (en)
Inventor
Hans-Michael Eggenweiler
Michael Wolf
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7702358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ2004457(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CZ2004457A3 publication Critical patent/CZ2004457A3/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ2004457A 2001-10-12 2002-09-19 Použití inhibitorů fotodiesterasy IV CZ2004457A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10150517A DE10150517A1 (de) 2001-10-12 2001-10-12 Verwendung von Phosphodiesterase IV-Inhibitoren

Publications (1)

Publication Number Publication Date
CZ2004457A3 true CZ2004457A3 (cs) 2005-04-13

Family

ID=7702358

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2004457A CZ2004457A3 (cs) 2001-10-12 2002-09-19 Použití inhibitorů fotodiesterasy IV

Country Status (15)

Country Link
US (1) US20040235845A1 (enExample)
EP (1) EP1435958A1 (enExample)
JP (1) JP2005505604A (enExample)
KR (1) KR20050028900A (enExample)
CN (1) CN1564687A (enExample)
AR (1) AR037741A1 (enExample)
AU (1) AU2002338734B2 (enExample)
CA (1) CA2460135C (enExample)
CZ (1) CZ2004457A3 (enExample)
DE (1) DE10150517A1 (enExample)
HU (1) HUP0401641A3 (enExample)
MX (1) MXPA04002639A (enExample)
NO (1) NO20041938L (enExample)
SK (1) SK1652004A3 (enExample)
WO (1) WO2003032993A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023253A1 (en) * 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
AU2005210042B2 (en) 2004-02-04 2011-04-21 Takeda Gmbh 2-(piperidin-4-yl) -4, 5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
MX2007010560A (es) 2005-03-08 2008-02-21 Nycomed Gmbh Roflumilast para el tratamiento de diabetes mellitus.
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
UA100497C2 (ru) 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
RU2626677C1 (ru) * 2016-03-09 2017-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение фармацевтической композиции 2-морфолино-5-фенил-6н-1,3,4-тиадиазина с аскорбиновой кислотой в качестве средства коррекции аллоксанового сахарного диабета
MA59016B1 (fr) * 2022-12-30 2024-09-30 Université Ibn Tofail Nouveaux composés hétérocycliques de type 1,3,4-thiadiazines pour le traitement du diabète de type 2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134893A1 (de) * 1991-10-23 1993-04-29 Merck Patent Gmbh Thiadiazinone
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
DE19502699A1 (de) * 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone
DE19514568A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl-pyridazinone
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
GB9525262D0 (en) * 1995-12-11 1996-02-07 Bayer Ag Heterocyclylcarbonyl substituted benzofuranyl-ureas
DE19604388A1 (de) * 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives

Also Published As

Publication number Publication date
SK1652004A3 (sk) 2005-05-05
HUP0401641A2 (hu) 2004-11-29
CA2460135C (en) 2010-08-24
MXPA04002639A (es) 2004-06-07
KR20050028900A (ko) 2005-03-23
US20040235845A1 (en) 2004-11-25
CA2460135A1 (en) 2003-04-24
EP1435958A1 (de) 2004-07-14
WO2003032993A1 (de) 2003-04-24
HUP0401641A3 (en) 2007-02-28
JP2005505604A (ja) 2005-02-24
AU2002338734B2 (en) 2007-11-08
NO20041938L (no) 2004-05-11
DE10150517A1 (de) 2003-04-17
AR037741A1 (es) 2004-12-01
CN1564687A (zh) 2005-01-12

Similar Documents

Publication Publication Date Title
US11970481B1 (en) Substituted pyridine derivatives as SARM1 inhibitors
Youssef et al. Synthesis and biological evaluation of novel pyrazolyl-2, 4-thiazolidinediones as anti-inflammatory and neuroprotective agents
CZ2004457A3 (cs) Použití inhibitorů fotodiesterasy IV
KR101345497B1 (ko) 설폰아미드 유도체
US20100168084A1 (en) Therapeutic compounds and related methods of use
EP3444249B1 (en) Sodium channel blockers, preparation method thereof and use thereof
CZ20004896A3 (en) Pharmaceutical preparation containing inhibitor COX-2 and inhibitor iNOS
JP2000507545A (ja) Cns損傷についての新規な治療
FI90235C (fi) Menetelmä eläinlääketieteellisesti käyttökelpoisten -aryyli-4-(4,5-dihydro-3,5-diokso-1,2,4-triatsin-2(3H)-yyli)bentseeniasetonitriilien valmistamiseksi
HUP0203376A2 (hu) Ciklooxigenáz-2 inhibitor hatású 5-aril-1h-1,2,4-triazol-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2359104T3 (es) Derivados de tiadiazol para el tratamiento de enfermedades neurodegenerativas.
SK287362B6 (sk) Derivát arylalkanoylpyridazínu, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
US20040072851A1 (en) Medicinal compositions for treating lower uropathy
WO2003031434A1 (en) Compounds and methods
WO2008019106A1 (en) Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
Asif General study of pyridazine compounds against cyclooxygenase enzyme and their relation with analgesic, anti-inflammatory and anti-arthritic activities
ZA200503383B (en) 3,4,-Disubstituted pyrroles and their use in treating inflammatory diseases
KR20090020703A (ko) 정신과 질환을 치료하기 위한 p38 키나아제 억제제의 용도
JPH11302177A (ja) 腎炎治療剤
CN100546581C (zh) 用于治疗神经病学病症的包含抗癫痫药的组合
JP7324930B2 (ja) カルバメート置換スチリルスルホン類化合物及びその製造方法ならびにその使用
WO1999059524A2 (es) Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica
SK7062001A3 (en) Remedial agent for erectile dysfunction
Sorbera et al. Cimicoxib
EP1864663A1 (en) Preventive and/or therapeutic agent for rheumatoid arthritis